Olivier Lavergne
Overview
Explore the profile of Olivier Lavergne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Derwael C, Lavergne O, Lovinfosse P, Nechifor V, Salve M, Waltregny D, et al.
EJNMMI Res
. 2020 Mar;
10(1):15.
PMID: 32112230
Background: Prostate-specific membrane antigen (PSMA) ligand PET/CT has already provided promising results in prostate cancer (PC) imaging, yet simple and reproductible reporting criteria are still lacking. This study aimed at...
2.
Ayoub M, Damian M, Gespach C, Ferrandis E, Lavergne O, de Wever O, et al.
J Biol Chem
. 2009 Aug;
284(42):29136-45.
PMID: 19648112
The simultaneous activation of many distinct G protein-coupled receptors (GPCRs) and heterotrimeric G proteins play a major role in various pathological conditions. Pan-inhibition of GPCR signaling by small molecules thus...
3.
Brezak M, Valette A, Quaranta M, Contour-Galcera M, Jullien D, Lavergne O, et al.
Int J Cancer
. 2008 Dec;
124(6):1449-56.
PMID: 19065668
CDC25 phosphatases are key actors in cyclin-dependent kinases activation whose role is essential at various stages of the cell cycle. CDC25 expression is upregulated in a number of human cancers....
4.
Lavergne O, Fernandes A, Brehu L, Sidhu A, Brezak M, Prevost G, et al.
Bioorg Med Chem Lett
. 2005 Oct;
16(1):171-5.
PMID: 16216500
A focused set of heterocyclic quinones based on the benzothiazole, benzoxazole, benzimidazole, indazole and isoindole was prepared and screened with respect to the inhibition of the phosphatase activity of CDC25C....
5.
Brezak M, Quaranta M, Contour-Galcera M, Lavergne O, Mondesert O, Auvray P, et al.
Mol Cancer Ther
. 2005 Sep;
4(9):1378-87.
PMID: 16170030
Cell cycle regulators, such as the CDC25 phosphatases, are potential targets for the development of new anticancer drugs. Here we report the identification and the characterization of BN82685, a quinone-based...
6.
Contour-Galcera M, Lavergne O, Brezak M, Ducommun B, Prevost G
Bioorg Med Chem Lett
. 2004 Oct;
14(23):5809-12.
PMID: 15501045
A targeted library of small molecules has been prepared to optimize the biological activity of BN82002, our initial lead compound, recently described as an original inhibitor of CDC25 phosphatases. Some...
7.
Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Camara J, et al.
Cancer Res
. 2004 Jul;
64(14):4942-9.
PMID: 15256467
BN80927 belongs to a novel family of camptothecin analogs, the homocamptothecins, developed on the concept of topoisomerase I (Topo I) inhibition and characterized by a stable seven-membered beta-hydroxylactone ring. Preclinical...
8.
Brezak M, Quaranta M, Mondesert O, Galcera M, Lavergne O, Alby F, et al.
Cancer Res
. 2004 May;
64(9):3320-5.
PMID: 15126376
CDC25 dual-specificity phosphatases are essential regulators that dephosphorylate and activate cyclin-dependent kinase/cyclin complexes at key transitions of the cell cycle. CDC25 activity is currently considered to be an interesting target...
9.
Prevost G, Brezak M, Goubin F, Mondesert O, Galcera M, Quaranta M, et al.
Prog Cell Cycle Res
. 2003 Nov;
5:225-34.
PMID: 14593717
As essential cell cycle regulators, the CDC25 phosphatases are currently considered as potential targets for the development of novel therapeutic approaches. Here, we review the function and regulation of CDC25...